Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

J&J’s Ebola Vaccine Demonstrated Promising Antibody Immune Responses In Adults & Children

By John F. Heerdink, Jr.

As per reports, Johnson & Johnson (JNJ) Ebola vaccine regimen has demonstrated promising antibody immune responses in adults and children, as published in Lancet Infectious Diseases journal. J&J informed that the two-dose regimen was well-accepted and released antibody responses to the Zaire ebolavirus species after 21 days in 98% of the participants, on receiving the second dose. The two-dose combination, Zabdeno, and Mvabea immune responses lasted in adults for at least two years. It was further noted that a booster shot administered two years after the initial vaccination induced a strong immune response within seven days.

“These peer-reviewed data support the prophylactic use of the Johnson & Johnson Ebola vaccine regimen to protect people at risk of Ebola, which is essential to our vision of preventing Ebola outbreaks before they can begin,” stated J&J’s Chief Scientific Officer Paul Stoffels.

 Vaccines, updated treatments have proven to be highly effective in reducing Ebola fatality rates. The company’s vaccine regimen had received European approval in July 2020 and prequalification from the WHO, which allowed medicines to be procured by developing countries, in April 2021.

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.

(Read Original Story: UPDATE 1-J&J reports promising Ebola vaccine data in Reuters)